The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.

A time-to-event modeling analysis of DAPA-CKD trial data projected that dapagliflozin delays the mean time to kidney failure by approximately 6.6 years in the DAPA-CKD population, with similar long-term cardiorenal benefits in a broader pooled CKD population.